Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP796171.RA7TN2aeLdeBrlK6S5S_ky-NKZh3eH226Ihe9a8DSKXR8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP796171.RA7TN2aeLdeBrlK6S5S_ky-NKZh3eH226Ihe9a8DSKXR8130_assertion type Assertion NP796171.RA7TN2aeLdeBrlK6S5S_ky-NKZh3eH226Ihe9a8DSKXR8130_head.
- NP796171.RA7TN2aeLdeBrlK6S5S_ky-NKZh3eH226Ihe9a8DSKXR8130_assertion description "[To test the biologic activity of 13-cis retinoic acid (13-CRA) in patients with myelodysplastic states (MDS), we administered 13-CRA orally (2.5 mg/kg/d initially, escalated to 4 mg/kg/d) for 8 weeks to 15 consecutive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP796171.RA7TN2aeLdeBrlK6S5S_ky-NKZh3eH226Ihe9a8DSKXR8130_provenance.
- NP796171.RA7TN2aeLdeBrlK6S5S_ky-NKZh3eH226Ihe9a8DSKXR8130_assertion evidence source_evidence_literature NP796171.RA7TN2aeLdeBrlK6S5S_ky-NKZh3eH226Ihe9a8DSKXR8130_provenance.
- NP796171.RA7TN2aeLdeBrlK6S5S_ky-NKZh3eH226Ihe9a8DSKXR8130_assertion SIO_000772 3514807 NP796171.RA7TN2aeLdeBrlK6S5S_ky-NKZh3eH226Ihe9a8DSKXR8130_provenance.
- NP796171.RA7TN2aeLdeBrlK6S5S_ky-NKZh3eH226Ihe9a8DSKXR8130_assertion wasDerivedFrom befree-20140225 NP796171.RA7TN2aeLdeBrlK6S5S_ky-NKZh3eH226Ihe9a8DSKXR8130_provenance.
- NP796171.RA7TN2aeLdeBrlK6S5S_ky-NKZh3eH226Ihe9a8DSKXR8130_assertion wasGeneratedBy ECO_0000203 NP796171.RA7TN2aeLdeBrlK6S5S_ky-NKZh3eH226Ihe9a8DSKXR8130_provenance.